FOP Australia
Non-Profit & Charitable Organizations · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Speed Ave, North Plympton, South Austr...Website
www.fopaustralia.orgRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About FOP Australia
FOP Australia is dedicated to supporting individuals with Fibrodysplasia Ossificans Progressiva (FOP) in Australia and New Zealand. The organization provides essential information, resources, and community connections for patients and their families dealing with this rare genetic condition. FOP Australia also raises awareness and funds for medical research and treatment options, ensuring equitable access to emerging therapies. Established in 2015, the organization aims to improve the quality of life for those affected by FOP through advocacy and support services.Explore more
FOP Australia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is FOP Australia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at FOP Australia
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if FOP Australia is spiking on competitors!
Check if FOP Australia has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when FOP Australia launches new products
FOP Australia, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if FOP Australia had a recent Job posting/layoffs
Earning: See what the market has to say on FOP Australia recently announced quarterly report
Funding: Get notified immidiatlly once FOP Australia has new funding data
Recommended Actions
Find VP level buyers at FOP Australia
Find 2 more new buyers
Compare Similar Companies to FOP Australia
Compare insights from companies similar to FOP Australia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
FOP Australia is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
FOP Australia is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about FOP Australia.
FOP Australia Tech Stack
A closer look at the technologies used by FOP Australia
FOP Australia News & Media
Ipsen Confirms U.S. FDA Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (FOP)
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that its New Drug Application (NDA) for palovarotene, an oral, investigational, selective RARγ agonist for the prevention of heterotopic ossification (new bone formation) as a potential treatment option for people living with the progressive disabling and ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP), has been accepted by the U.S. Food and Drug Administration (FDA). The target reIpsen to Present New Insights at ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP), Including Global Phase III MOVE Trial Results
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN: ADR: IPSEY) today announced that it will share data from the company’s growing Rare Diseases Therapeutic Area portfolio, with seven presentations at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting (September 11-15, 2020). These include the oral presentation of Ipsen’s MOVE trial (during the Novel Therapies for Rare Bone Disease session on Saturday, 12 September [11:00am - 12:15pm ET]), the first and only muIpsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting
PARIS--(BUSINESS WIRE)--Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during an oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2020 annual meeting (Saturday, 12 September, 11:00am - 12:30pm ET). Dosing of palovarotene in the MOVE clinical trial was paused when futility criteria were met at a pre-specified interim analysiIpsen Provides Update on Palovarotene Clinical Programs
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will begin to reinitiate palovarotene dosing in patients 14 years of age and older currently participating in its fibrodysplasia ossificans progressiva (FOP) clinical program. The Food and Drug Administration (FDA) in the U.S. has confirmed they have no safety concerns with restarting dosing in patients 14 years of age and older. Clearance to reinitiate dosing in these patients has also been receiv
Read more news
Top Non-Profit & Charitable Organizations Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding FOP Australia
Sign Up For FreeTo access detailed company insights
FOP Australia is dedicated to supporting individuals with Fibrodysplasia Ossificans Progressiva (FOP) in Australia and New Zealand. The organization provides essential information, resources, and community connections for patients and their families dealing with this rare genetic condition. FOP Australia also raises awareness and funds for medical... Read More
